Fudan University Shanghai cancer Center Therapeutic Targets of Cancer EGFR Cyclin-dependent inhibitors kinase inhibitors Sustaining Aerobic glycolysis proliferative Immune activating inhibitors suppressors anti-CTLA4 mAb Deregulating Avoiding cellular mmune energetic Proapoptotic Resisting ase BH3 mimetics =← Inhibitors nstability promoting inflammation PARP Activating Selective anti- inhibitors inflammatory drugs Inhibitors of Inhibitors of VEGF signaling HGF/C-Met 复旦大学上海医学院肿瘤学糸 Hanahan. et al. Cell 2011: 144: 646
Fudan University Shanghai Cancer Center 复旦大学上海医学院肿瘤学系 6 Therapeutic Targets of Cancer Hanahan D, et al. Cell. 2011;144:646
Fudan University Shanghai cancer Center Proved and Actively Tested Targets Ligand-targeted apeutic Therapy Antibodies ± Toxins Metalloproteinase Inhibitors Growth Antigens Factor Receptors Immunotherapy Tyrosine Kinase Inhibitors(Glivec, Gefitinib Cancer Intracellular Cell Signaling Molecules Apoptosis Agonists m-RNA Antisense Angiogenesis Inhibitors (Angiostatin, Endostatin& Avastin) 复旦大学上海医学院肿瘤学糸
Fudan University Shanghai Cancer Center 复旦大学上海医学院肿瘤学系 7 Proved and Actively Tested Targets
Fudan University Shanghai cancer Center Molecular Targets BCR-ABL chronic myeloid leukemia(CML) EGFR(Epidermal Growth Factor Receptor) non-small-cell lung cancer(NSCLC), colorectal cancer, head neck cancer ■HER2 breast cancer, gastric cancer VEGF (vascular endothelial growth factor) non-small-cell lung cancer(NSCLC), colorectal cancer, renal cell cancer(RCC) - CD20 B-cell lymphoma 8 复旦大学上海医学院肿瘤学糸
Fudan University Shanghai Cancer Center 复旦大学上海医学院肿瘤学系 8 Molecular Targets ▪ BCR-ABL ﹣ chronic myeloid leukemia (CML) ▪ EGFR (Epidermal Growth Factor Receptor) ﹣ non-small-cell lung cancer (NSCLC), colorectal cancer, head & neck cancer ▪ HER2 ﹣ breast cancer, gastric cancer ▪ VEGF (vascular endothelial growth factor) ﹣ non-small-cell lung cancer (NSCLC), colorectal cancer, renal cell cancer (RCC) ▪ CD20 ﹣ B-cell lymphoma
Fudan University Shanghai cancer Center Types of Targeted Agents Tyrosine kinase receptor inhibitors gefitinib, erlotinib, sunitinib, sorafenib Angiogenesis inhibitors sunitinib. sorafenib, bevacizumab Proteasome inhibitors Immunotherapy(monoclonal antibodies) cetuximab, trastuzumab, rituximab 9 复旦大学上海医学院肿瘤学糸
Fudan University Shanghai Cancer Center 复旦大学上海医学院肿瘤学系 9 Types of Targeted Agents ▪ Tyrosine kinase receptor inhibitors ﹣gefitinib, erlotinib, sunitinib, sorafenib ▪ Angiogenesis inhibitors ﹣sunitinib, sorafenib, bevacizumab ▪ Proteasome inhibitors ▪ Immunotherapy (monoclonal antibodies) ﹣cetuximab, trastuzumab, rituximab
Fudan University shanghai cancer Center Molecular Target: BCR-ABL 10 复旦大学上海医学院肿瘤学糸
Fudan University Shanghai Cancer Center 复旦大学上海医学院肿瘤学系 10 Molecular Target: BCR-ABL